Chronic migraine prevention with topiramate by unknown
Introduction
Migraine is a common and debilitating disorder with a 1-
year prevalence of approximately 18% in women and 6%
in men [1]. Chronic migraine (CM) is even more incapac-
itating; it is prevalent in the general population, affecting
2%–3% of individuals [2]. CM has been recently added to
the new International Headache Society (IHS) classifica-
tion system [3]. It is one of the most frequent conditions
found in headache centres, but, to date, there is still no sat-
isfactory therapeutic approach for these patients.
The major medication groups for the preventive treat-
ment of migraine include beta-adrenergic blockers, anti-
depressants, calcium channel antagonists, serotonin anta-
gonists, anti-convulsants, non-steroidal anti-inflammatory
drugs (NSAIDs) and others (including riboflavin, miner-
als and herbs).
Neuromodulators have been increasingly recommend-
ed for migraine prevention because of placebo-controlled,
double-blind trials that prove it to be effective.
Topiramate has been proven effective for episodic
migraine prevention, but little is known about the efficacy
of topiramate in CM preventive treatment. We did a study
to evaluate the role of topiramate in CM.
Methods
Sixty-four patients diagnosed with chronic migraine or probable
chronic migraine according to the IHS diagnostic criteria [3]
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Abstract Chronic migraine (CM) is
a disabling condition with not many
treatment strategies available.
Topiramate is effective in episodic
migraine prevention, however little
is known about its effect in CM. An
open label study was performed.
Sixty-four patients diagnosed with
CM or probable CM according to
the IHS diagnostic criteria were
enrolled, 50 patients were available
for analysis and an intention-to-treat
methodology was applied. The pri-
mary endpoint considered was the
number of patients with a decrease
in headache frequency higher than
50%. The median dose was 100 mg,
a reduction in frequency higher than
50% occurred in 33 patients (66%)
and 14 (28%) presented a complete
response, defined as a frequency
reduction higher than 95%. The
medication was well tolerated. The
most common side effects found
were weight loss, paraesthesias,
nausea, cognitive dysfunction,
fatigue, somnolence, insomnia and
depression. Our findings suggest
that topiramate is effective in CM
prophylaxis.
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were enrolled. Exclusion criteria were carbonic anhydrase (CA)
inhibitors, history of renal calculi, pregnancy or lactation.
Patients with neurological diseases or taking any prophylactic
treatment for headache at the time of our observation were also
excluded. Fourteen patients dropped out of the study because
they were lost to follow-up (8 patients) or had adverse events
(somnolence in 2, cognitive dysfunction in 2, epigastralgia 1,
depression 1). The patients were lost to follow-up because:
moved to another state (1), denied pharmacological treatment,
not because of side effects (2), gave up participating in a clinical
trial (5). Fifty patients (40 women, 10 men) were evaluated by
the intention-to-treat methodology. The primary endpoint con-
sidered was the number of patients with a decrease in headache
frequency higher than 50%. All patients received topiramate
25–200 mg, mean dose of 91 mg, median dose 100 mg. A titra-
tion schedule was provided over the first month, with follow-ups
every 4 weeks for 12 weeks. The headache diaries were collect-
ed and data on headache frequency, intensity, duration and anal-
gesic consumption were evaluated. All patients gave their
informed consent to participate. The study was approved by the
Local Ethics Committee.
One-way repeated measures analysis of variance was used to
compare values between the four time periods. Tukey’s method
was used for post hoc pairwise comparisons. The Fisher and chi-
square tests were applied for 2x2 analysis. All p-values reported
were two-tailed and values lower than 0.05 were considered sig-
nificant.
Results
The mean age was 41.4±11.7 years. Body mass index
(BMI) mean was 24.7. Thirty-one patients had normal
BMIs, 12 patients were overweight and 7 had a BMI high-
er than 30. Thirty-nine patients presented a history of
acute medication overuse, 32 with simple/combination
analgesics, 9 with triptans, 8 ergotamines and 3 NSAIDs.
The mean history of headaches was 20.5 years, and the
mean history of daily headaches was 4.7 years.
The primary endpoint, headache response higher than
50% in frequency reduction, was achieved by 33 patients
(66%). Eight (16%) patients did not respond and 9 (18%)
had a less than 50% reduction. Fourteen (28%) presented
a complete response, defined as a frequency reduction
higher than 95%. No difference was found in response in
patients with or without acute medication. Twenty-five
patients who responded and 14 non-responders were
overusers (p=NS).
Frequency, duration and intensity were significantly
reduced (p<0.001) when comparing the first to the last
month of treatment. Results were already significant as
early as the first month. The mean weight loss found was
1.654 g, 2.75% of the body weight; 20% of the patients
lost more than 5% of body weight. The most common side
effects encountered were weight loss (in 38 patients,
76%), paraesthesias (24, 48%), nausea (6, 12%), cognitive
dysfunction (5, 10%), fatigue (4, 8%), somnolence (3,
6%), insomnia (2, 4%) and depression (2, 4%).
Discussion
In this open study we found a favourable response in
headache frequency, intensity and duration of CM patients
treated with topiramate. The side effect profile showed
topiramate to be a tolerable drug in CM patients. One
important finding is that headache response occurred
already in the first month of treatment. Another relevant
issue is that no significant difference in headache response
was found when patients with a history of acute medica-
tion overuse (although not fulfilling the criteria for med-
ication overuse headache) were compared to those with
pure chronic migraine.
Topiramate has been studied for migraine prevention
in large, placebo-controlled clinical trials. Topiramate was
superior to placebo as measured by reduction in monthly
migraine frequency, overall 50% responder rate, reduction
in monthly migraine days and reduction in the rate of
daily rescue medication use in all trials [4–6]. The target
dose appeared to be 100 mg.
Although there is published data available from recent
studies with large numbers of patients included, long
observation periods and good methodology, the most crit-
ical patient group for the clinician in a tertiary headache
centre, chronic migraineurs, has not been properly inves-
tigated. Silvestrini et al. [7] showed the efficacy of topira-
mate in chronic migraine with analgesic overuse preven-
tive treatment. Only 28 patients were studied receiving
topiramate in a lower dose (50 mg). A significantly lower
28-day headache frequency in comparison to those treated
with placebo was observed.
Our study shows that topiramate in a median dose of
100 mg is effective and well tolerated in chronic migraine
prevention. We decided to include both acute medication
overuse patients and non-overusers in our study, because
the sample population would be closer to the clinical pro-
file found in headache centres, therefore the results
express a more real clinical scenario. Placebo-controlled
trials are required for a better understanding of the clini-
cal response of chronic migraine with topiramate preven-
tive treatment.
Pathophysiological considerations suggest that the
possible basis for the shift from episodic to chronic
headache can be progressive damage to the central noci-
ceptive system [8]. The anti-convulsant activity of most
anti-epileptic drugs is thought to be due to a state-depen-
dent blockade of voltage-dependent Na+ or Ca2+ chan-
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nels, or an ability to enhance the activity of GABA at
GABAA receptors. Topiramate can influence the activity
of some types of voltage-activated Na+ and Ca2+ chan-
nels, GABAA receptors and the alpha-amino-3-hydroxy-
5-methylisoxazole-4-proprionic acid (AMPA)/kainate
subtype of glutamate receptors. Topiramate also inhibits
some isozymes of CA and exhibits selectivity for CA II
and CA IV [9].
We have recently shown that chronic migraine is relat-
ed to a hyperglutamatergic state in the brain, confirmed by
higher cerebrospinal fluid glutamate levels in chronic
migraineurs compared to controls [10]. Therefore, topira-
mate may be a candidate for chronic migraine prevention.
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